As Abbott pursues Perrigo and fends off Teva Pharmaceutical, expect to see the drugmaker tap its bankroll for acquisitions, both big and small

To read the entire story, you must be logged in.
Please log in now or register with us.

How useful was this post?

Tell us more about your rating decision